|
Continuation of d10: dtpa2qq crt-d, implanted (b)(6) 2024 medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
It was reported that approximately one month post implant procedure of the device and an absorbable antibacterial envelope, the patient developed clear fluid that was draining from the procedure incision.It was noted that the patient did not have a fever.Antibiotics were administered.It was further reported that there was a small wound dehiscence noted, steri strips were applied to the wound.It was noted that there were no signs of an infection and the antibiotics were prophylactic.The cardiac resynchronization therapy defibrillator (crt-d) system and antibacterial absorbable envelope remain in use.The patient is a participant in a clinical study.No further patient complications have been reported as a result of this event.
|